Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation

Takaaki Yamada, Toshiharu Nonaka, Takahisa Yano, Toshio Kubota, Nobuaki Egashira, Takehiro Kawashiri, Ryozo Oishi

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

The purpose of this study was (i) to determine the optimal dosage of teicoplanin for each patient group stratified by renal function and weight based on a population pharmacokinetic model and observed distribution of patient characteristics and (ii) to develop new simplified dosing regimens designed to achieve 15-30 μg/mL. Patient data were collected retrospectively from routine therapeutic drug monitoring files of adult patients who were given the standard loading dose regimen of teicoplanin (400 mg twice on Day 1, followed by 400 mg once daily for 2 days) and whose trough concentration was measured just before administration on Day 4. Monte Carlo simulation was conducted to estimate the trough concentration at 72 h after the initial loading dose (Cmin 72 h) and at steady state (Css min). The percentage of observed Cmin 72 h in patients who received the standard loading dose regimen outside the non-parametric 90% prediction interval (from 5th to 95th percentile) of the simulated Cmin 72 h was <10%. Simplified loading dose and maintenance dose regimens for each group stratified by renal function and weight were created to achieve Cmin 72 h and Css min of 15 μg/mL and 20-25 μg/mL, respectively. The percentage of Cmin 72 h and Css min in the range 15-30 μg/mL was 43-65% and 61-82% across each renal function and weight strata, respectively. These new simplified dosing regimens of teicoplanin could be helpful in individual adjustment of the loading and maintenance doses to achieve 15-30 μg/mL.

元の言語英語
ページ(範囲)344-348
ページ数5
ジャーナルInternational Journal of Antimicrobial Agents
40
発行部数4
DOI
出版物ステータス出版済み - 10 1 2012

Fingerprint

Teicoplanin
Kidney
Weights and Measures
Drug Monitoring
Pharmacokinetics
Population

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

これを引用

Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation. / Yamada, Takaaki; Nonaka, Toshiharu; Yano, Takahisa; Kubota, Toshio; Egashira, Nobuaki; Kawashiri, Takehiro; Oishi, Ryozo.

:: International Journal of Antimicrobial Agents, 巻 40, 番号 4, 01.10.2012, p. 344-348.

研究成果: ジャーナルへの寄稿記事

@article{678161122fef4250a5fb8990401f1025,
title = "Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation",
abstract = "The purpose of this study was (i) to determine the optimal dosage of teicoplanin for each patient group stratified by renal function and weight based on a population pharmacokinetic model and observed distribution of patient characteristics and (ii) to develop new simplified dosing regimens designed to achieve 15-30 μg/mL. Patient data were collected retrospectively from routine therapeutic drug monitoring files of adult patients who were given the standard loading dose regimen of teicoplanin (400 mg twice on Day 1, followed by 400 mg once daily for 2 days) and whose trough concentration was measured just before administration on Day 4. Monte Carlo simulation was conducted to estimate the trough concentration at 72 h after the initial loading dose (Cmin 72 h) and at steady state (Css min). The percentage of observed Cmin 72 h in patients who received the standard loading dose regimen outside the non-parametric 90{\%} prediction interval (from 5th to 95th percentile) of the simulated Cmin 72 h was <10{\%}. Simplified loading dose and maintenance dose regimens for each group stratified by renal function and weight were created to achieve Cmin 72 h and Css min of 15 μg/mL and 20-25 μg/mL, respectively. The percentage of Cmin 72 h and Css min in the range 15-30 μg/mL was 43-65{\%} and 61-82{\%} across each renal function and weight strata, respectively. These new simplified dosing regimens of teicoplanin could be helpful in individual adjustment of the loading and maintenance doses to achieve 15-30 μg/mL.",
author = "Takaaki Yamada and Toshiharu Nonaka and Takahisa Yano and Toshio Kubota and Nobuaki Egashira and Takehiro Kawashiri and Ryozo Oishi",
year = "2012",
month = "10",
day = "1",
doi = "10.1016/j.ijantimicag.2012.05.025",
language = "English",
volume = "40",
pages = "344--348",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation

AU - Yamada, Takaaki

AU - Nonaka, Toshiharu

AU - Yano, Takahisa

AU - Kubota, Toshio

AU - Egashira, Nobuaki

AU - Kawashiri, Takehiro

AU - Oishi, Ryozo

PY - 2012/10/1

Y1 - 2012/10/1

N2 - The purpose of this study was (i) to determine the optimal dosage of teicoplanin for each patient group stratified by renal function and weight based on a population pharmacokinetic model and observed distribution of patient characteristics and (ii) to develop new simplified dosing regimens designed to achieve 15-30 μg/mL. Patient data were collected retrospectively from routine therapeutic drug monitoring files of adult patients who were given the standard loading dose regimen of teicoplanin (400 mg twice on Day 1, followed by 400 mg once daily for 2 days) and whose trough concentration was measured just before administration on Day 4. Monte Carlo simulation was conducted to estimate the trough concentration at 72 h after the initial loading dose (Cmin 72 h) and at steady state (Css min). The percentage of observed Cmin 72 h in patients who received the standard loading dose regimen outside the non-parametric 90% prediction interval (from 5th to 95th percentile) of the simulated Cmin 72 h was <10%. Simplified loading dose and maintenance dose regimens for each group stratified by renal function and weight were created to achieve Cmin 72 h and Css min of 15 μg/mL and 20-25 μg/mL, respectively. The percentage of Cmin 72 h and Css min in the range 15-30 μg/mL was 43-65% and 61-82% across each renal function and weight strata, respectively. These new simplified dosing regimens of teicoplanin could be helpful in individual adjustment of the loading and maintenance doses to achieve 15-30 μg/mL.

AB - The purpose of this study was (i) to determine the optimal dosage of teicoplanin for each patient group stratified by renal function and weight based on a population pharmacokinetic model and observed distribution of patient characteristics and (ii) to develop new simplified dosing regimens designed to achieve 15-30 μg/mL. Patient data were collected retrospectively from routine therapeutic drug monitoring files of adult patients who were given the standard loading dose regimen of teicoplanin (400 mg twice on Day 1, followed by 400 mg once daily for 2 days) and whose trough concentration was measured just before administration on Day 4. Monte Carlo simulation was conducted to estimate the trough concentration at 72 h after the initial loading dose (Cmin 72 h) and at steady state (Css min). The percentage of observed Cmin 72 h in patients who received the standard loading dose regimen outside the non-parametric 90% prediction interval (from 5th to 95th percentile) of the simulated Cmin 72 h was <10%. Simplified loading dose and maintenance dose regimens for each group stratified by renal function and weight were created to achieve Cmin 72 h and Css min of 15 μg/mL and 20-25 μg/mL, respectively. The percentage of Cmin 72 h and Css min in the range 15-30 μg/mL was 43-65% and 61-82% across each renal function and weight strata, respectively. These new simplified dosing regimens of teicoplanin could be helpful in individual adjustment of the loading and maintenance doses to achieve 15-30 μg/mL.

UR - http://www.scopus.com/inward/record.url?scp=84866018378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866018378&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2012.05.025

DO - 10.1016/j.ijantimicag.2012.05.025

M3 - Article

C2 - 22818770

AN - SCOPUS:84866018378

VL - 40

SP - 344

EP - 348

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 4

ER -